Back to Browse Journals » Open Access Journal of Clinical Trials » Volume 2

Research methodological issues in evaluating herbal interventions

Authors Dipika Bansal, Debasish Hota, Amitava Chakrabarti

Published 17 February 2010 Volume 2010:2 Pages 15—21


Review by Single-blind

Peer reviewer comments 3

Dipika Bansal, Debasish Hota, Amitava Chakrabarti

Postgraduate Institute of Medical Education and Research, Chandigarh, India

Abstract: Randomized controlled trials provide the best evidence, and is seen as the gold standard for allopathic research. Herbal therapies are not an integral part of conventional care although they are still used by patients in their health care management. These medicines need to be subjected to rigorous research to establish their effectiveness and safety. Clearly defined treatments are required and should be recorded in a manner that enables other suitably trained researchers to reproduce them reliably. Quality control of herbal products is also a prerequisite of credible clinical trials. Methodological strategies for investigating the herbal interventions and the issues regarding appropriate patient selection, randomization and blinding, placebo effects and choice of comparator, occupational standardization and the selection of appropriate study endpoints to prove efficacy are being discussed. This paper will review research options and propose some suggestions for future research design.
Keywords: CAM research, herbal therapies, methodology, clinical trial

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Profile of efraloctocog alfa and its potential in the treatment of hemophilia A

George LA, Camire RM

Journal of Blood Medicine 2015, 6:131-141

Published Date: 24 April 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries

Cimino E, Linari S, Malerba M, Halimeh S, Biondo F, Westfeld M

Patient Preference and Adherence 2014, 8:1713-1720

Published Date: 12 December 2014

Towards a framework for treatment effectiveness in schizophrenia

Juckel G, de Bartolomeis A, Gorwood P, Mosolov S, Pani L, Rossi A, Sanjuan J

Neuropsychiatric Disease and Treatment 2014, 10:1867-1878

Published Date: 24 September 2014

Managing hemophilia: the role of mobile technology

Khair K, Holland M

Smart Homecare Technology and TeleHealth 2014, 2:39-44

Published Date: 6 May 2014

The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al

International Journal of Nanomedicine 2010, 5:581-591

Published Date: 6 August 2010

Treatment of lumbar disc herniation: Evidence-based practice

Andrew J Schoenfeld, Bradley K Weiner

International Journal of General Medicine 2010, 3:209-214

Published Date: 9 July 2010